- Current report filing (8-K)
25 March 2010 - 5:31AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
Current
Report Pursuant to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
March
19, 2010
Date of
Report (Date of earliest event reported)
OSI PHARMACEUTICALS,
INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
0-15190
|
|
13-3159796
|
(State
or other jurisdiction of
incorporation)
|
|
(Commission
File
Number)
|
|
(I.R.S.
Employer
Identification
No.)
|
41
Pinelawn Road
Melville,
NY 11747
(Address
of principal executive offices)
(631)
962-2000
(Registrant's
telephone number, including area code)
N
/
A
(Former
name or former address,
if
changed since last report.)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
¨
|
Written
communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a
12)
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
8.01. Other Events.
On March
19, 2010, OSI Pharmaceuticals, Inc. (“OSI”) issued a press release announcing
that its international partner for Tarceva
®
(erlotinib), Roche, informed OSI that the European Committee for Medicinal
Products for Human Use has issued a positive opinion recommending approval of
Tarceva
as monotherapy for maintenance treatment
in patients with locally advanced or metastatic non-small cell lung
cancer with stable disease following
four cycles of standard
platinum-bas
ed first-line
chemotherapy.
A
copy of OSI’s press release, dated March 19, 2010, is attached hereto as
Exhibit 99.1 and is incorporated herein by reference.
On March
22, 2010, OSI issued a press release announcing the delivery of a Notice of
Redemption to all holders of its 3.25% Convertible Senior Subordinated Notes due
2023. A copy of OSI’s press release, dated March 22, 2010, is
attached hereto as Exhibit 99.2 and is incorporated herein by
reference.
Item 9.01. Financial Statements and
Exhibits.
Exhibit No.
|
Description
|
99.1
|
Press
release
date
d March 19,
2010.
|
99.2
|
Press
release
date
d March 22,
2010.
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Date:
March 24, 2010
|
OSI
PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Barbara A. Wood
|
|
|
Barbara
A. Wood
|
|
|
Senior
Vice President, General Counsel and
Secretary
|
EXHIBIT
INDEX
Exhibit No.
|
Description
|
99.1
|
Press release dated March 19,
2010.
|
99.2
|
Press release dated March 22,
2010.
|
Osi Pharmaceuticals (NASDAQ:OSIP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Osi Pharmaceuticals (NASDAQ:OSIP)
Historical Stock Chart
From Jul 2023 to Jul 2024